STOCK TITAN

Athira Pharma (ATHA) Net Income by Year

ATHA NASDAQ

Athira Pharma, Inc. reported a net loss of $106.0M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q2 FY2025 through Q1 FY2026, the same line adds up to a $129.4M net loss. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Athira Pharma, Inc. has filed alongside them.

FY2025 annual
Net Income -$106.0M
YoY n/m
5Y CAGR n/m

Ticker history: ATHA became LONA (LeonaBio, Inc.) on .

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

ATHA Net Income by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY25DEF 14AFY24DEF 14AFY2310-KFY2210-KFY2110-KFY2010-KFY1910-K
Net Income-$129.4M-$106.0Mn/m-$97.0Mn/m-$117.7Mn/m-$95.6Mn/m-$54.9Mn/m-$20.0Mn/m-$5.2M

TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings.

ATHA Net Income by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-QQ2'2310-Q
Net Income-$32.9Mn/m-$82.9Mn/m-$6.6Mn/m-$7.0Mn/m-$9.1Mn/m-$15.0M-$28.7Mn/m-$26.9Mn/m-$26.3Mn/mN/A-$33.0Mn/m-$29.6Mn/m

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Athira Pharma, Inc. financials

Frequently Asked Questions

Athira Pharma, Inc. reported a net loss of $106.0M in fiscal year 2025.

Athira Pharma, Inc. (ATHA) reported a $97.0M net loss in fiscal year 2024 and a $106.0M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Athira Pharma, Inc. (ATHA) reported a $129.4M net loss over the trailing 12 months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings.

Across the 7 fiscal years this page covers, Athira Pharma, Inc. (ATHA) net income went from -$5.2M in fiscal year 2019 to -$106.0M in fiscal year 2025.

Athira Pharma, Inc. (ATHA) reported -$32.9M in net income in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Athira Pharma, Inc. (ATHA) reported on that line in every period on record.